Walleye Capital LLC Decreases Stake in Medpace Holdings, Inc. $MEDP

Walleye Capital LLC reduced its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 34.5% during the first quarter, HoldingsChannel reports. The firm owned 5,995 shares of the company’s stock after selling 3,162 shares during the period. Walleye Capital LLC’s holdings in Medpace were worth $2,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its stake in Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock worth $2,086,000 after buying an additional 2,274 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Medpace in the fourth quarter valued at approximately $4,084,000. Cerity Partners LLC raised its stake in shares of Medpace by 41.0% in the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock valued at $45,478,000 after acquiring an additional 23,530 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of Medpace by 24,930.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock valued at $56,936,000 after acquiring an additional 100,968 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Medpace by 881.1% in the 4th quarter. SG Americas Securities LLC now owns 60,144 shares of the company’s stock worth $33,780,000 after acquiring an additional 54,014 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 14.7%

Medpace stock opened at $605.82 on Friday. The firm has a market capitalization of $17.30 billion, a P/E ratio of 35.51, a PEG ratio of 2.64 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The business has a 50-day moving average of $488.37 and a 200-day moving average of $493.74.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 109.14%. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the company posted $3.10 EPS. Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported second-quarter EPS of $4.25 and revenue of $707.3 million, both above expectations, showing that demand and execution remain strong. Medpace earnings report and conference call
• Positive Sentiment: The company raised fiscal 2026 guidance, signaling management has more confidence in its business momentum and future profitability. Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
• Positive Sentiment: Investors are also focusing on improving operating metrics, including a rebound in book-to-bill and a stronger backlog conversion rate, which suggest healthier future revenue visibility. Medpace: ‘Buy’ On Financial Metric Improvements And Solid Q2 2026 Earnings

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Robert W. Baird reaffirmed a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Mizuho boosted their price objective on Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Barclays set a $600.00 target price on Medpace in a report on Thursday. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Finally, Royal Bank Of Canada cut their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $502.00.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.